Addressing Sleep Disturbances of Parkinson Disease
Sleep disturbances may affect 40% to 90% of patients with PD, and a 2020 study found that about half of patients with PD had multiple sleep disorders.
Sleep disturbances may affect 40% to 90% of patients with PD, and a 2020 study found that about half of patients with PD had multiple sleep disorders.
To learn more about the potential role of cannabinoids in the management of sleep disorders, we interviewed Aleksandra M. Kwasnik, MD, who recently coauthored a review on the topic.
While there has recently been a surge in research regarding the complex relationship between sleep and epilepsy, there still remain gaps in knowledge that must be addressed.
Researchers investigated the incidence and risk factors of restless legs syndrome in pregnancy and their relationship to race and ethnicity.
The researchers found that the cumulative incidence of RLS in pregnancy was 18.1 percent for all women and 20.3, 15.4, 17.1, and 21.1 percent for White, Black, Hispanic, and Asian women.
Patients with primary restless leg syndrome who begin dopamine agonist (DA) therapy may be at increased risk for adverse psychiatric events.
Individuals with restless legs syndrome (RLS) have an increased risk for suicide and self-harm.
Several reports describe a possible association between restless legs syndrome and Parkinson disease, as well as Tourette syndrome and restless legs syndrome.
The aim of the review was to assess the safety and efficacy of oral and parenteral iron for the treatment of RLS.
For patients with restless leg syndrome, the primary motor cortex (M1) exhibits hyperexcitability, which is associated with disease severity.